{"filings":[{"id":2586797,"accession_number":"0001104659-26-104145","cik":1847367,"company_name":"ALUMIS INC.","ticker":"ALMS","form_type":"8-K","filed_at":"2026-09-01T12:30:46+00:00","items":["8.01","9.01"],"status":"ready","headline":"Alumis LUMUS Phase 2b misses primary endpoint in SLE; IFNGS-high subgroup shows robust responses","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["LUMUS Phase 2b (n=408) did not meet primary endpoint BICLA at Week 48 in overall SLE population.","Prespecified IFNGS-high subgroup showed robust responses on BICLA, CLASI-50, SRI-4, and LLDAS.","Dose-dependent target engagement with maximal suppression at 40mg BID; no new safety signals observed.","Alumis plans regulatory engagement to discuss Phase 3 development for envudeucitinib in SLE.","NDA submission for envudeucitinib in moderate-to-severe plaque psoriasis remains on track for 4Q 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2690080681.650258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2244080,"accession_number":"0001847367-26-000016","cik":1847367,"company_name":"ALUMIS INC.","ticker":"ALMS","form_type":"8-K","filed_at":"2026-08-13T20:07:36+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alumis Q2 2026: ONWARD3 shows 54% PASI 100; NDA on track for Q4","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ONWARD3: 75% PASI 90, 54% PASI 100 at 48 weeks (n=773) for envudeucitinib in PsO.","NDA submission for envudeucitinib in moderate-to-severe plaque psoriasis on track for Q4 2026.","Phase 2b LUMUS topline data in SLE expected Q3 2026; prioritizing Sjögren's and CLE.","Q2 net loss $142.2M vs net income $59.3M (incl. $187.9M ACELYRIN gain); $41.8M lonigutamab impairment.","Cash $502.3M; guidance funds into Q4 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2690080681.650258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2162198,"accession_number":"0001104659-26-093353","cik":1847367,"company_name":"ALUMIS INC.","ticker":"ALMS","form_type":"8-K","filed_at":"2026-08-10T20:06:06+00:00","items":["8.01","9.01"],"status":"ready","headline":"Envudeucitinib achieves 54% PASI 100 at 48 weeks; NDA on track for 4Q 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["54% of patients achieved PASI 100 (complete skin clearance) at 48 weeks; 75% achieved PASI 90.","Integrated analysis (890 pts) showed 66% PASI 90 and 47% PASI 100 at 48 weeks.","1,509 patients rolled into ONWARD3 from ONWARD1/2 (>85% rollover); safety consistent, no new signals.","NDA submission to FDA planned for 4Q 2026; LUMUS Phase 2b SLE topline expected 3Q 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2690080681.650258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1415959,"accession_number":"0001104659-26-080361","cik":1847367,"company_name":"ALUMIS INC.","ticker":"ALMS","form_type":"8-K","filed_at":"2026-07-02T20:30:31+00:00","items":["5.07"],"status":"ready","headline":"Alumis Inc. announces 2026 annual meeting results; elects three Class II directors and ratifies auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected James B. Tananbaum, Lynn Tetrault, and Zhengbin Yao as Class II directors for terms expiring 2029.","Ratified PricewaterhouseCoopers LLP as independent auditor for fiscal year 2026 with 105,924,017 votes for.","Broker non-votes of 18,824,099 on director elections; 123,432,072 shares outstanding as of record date.","Votes withheld for Yao: 13,930,883, significantly higher than for other director nominees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":2690080681.650258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1315596,"accession_number":"0001104659-26-078507","cik":1847367,"company_name":"ALUMIS INC.","ticker":"ALMS","form_type":"8-K","filed_at":"2026-06-29T12:01:35+00:00","items":["8.01","9.01"],"status":"ready","headline":"Alumis posts corporate presentation update; no material new data disclosed in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed a June 2026 corporate deck under Item 8.01 for investor meetings.","Exhibit 99.1 only contains a title slide; no clinical, financial, or pipeline specifics provided.","No guidance changes, trial results, or operational milestones mentioned in the filing.","Company ticker ALMS trades on Nasdaq; emerging growth company status reaffirmed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2690080681.650258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":442682,"accession_number":"0001847367-26-000009","cik":1847367,"company_name":"ALUMIS INC.","ticker":"ALMS","form_type":"8-K","filed_at":"2026-05-14T20:09:31+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alumis Q1 net loss $93.1M; Phase 3 envudeucitinib shows 68% PASI 90; NDA on track Q4 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $93.1M for Q1 2026; cash, equivalents and marketable securities $569.5M; runway into Q4 2027.","Phase 3 PsO: PASI 90 at Wk24: 68.0% and 62.1%; PASI 100: 41.0% and 39.5%; early quality-of-life improvements.","NDA submission for envudeucitinib in PsO on track Q4 2026; Phase 2b SLE topline data expected Q3 2026; TYK2 franchise update Q2 2026.","R&D expenses $81.5M (down from $96.6M); G&A $18.6M (down from $22.3M); exploring strategic alternatives for lonigutamab."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":1741000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2690080681.650258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109865,"accession_number":"0001104659-26-036386","cik":1847367,"company_name":"ALUMIS INC.","ticker":"ALMS","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Alumis Phase 3 envudeucitinib hits PASI 90/100 endpoints in plaque psoriasis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PASI 90 at Week 24: 68.0% (ONWARD1) and 62.1% (ONWARD2); PASI 100: 41.0% and 39.5%.","Early onset: PASI 90 separation vs placebo by Week 4; itch relief by Week 2; scalp clearance in ~30% by Week 4.","Safety profile consistent with Phase 2; no new signals, mainly mild AEs (headache, nasopharyngitis, URTI, acne).","Company to submit NDA to FDA in H2 2026; Phase 3 long-term extension (ONWARD3) ongoing.","Also evaluating envudeucitinib in SLE LUMUS Phase 2b with topline data expected Q3 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2690080681.650258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109864,"accession_number":"0001847367-26-000004","cik":1847367,"company_name":"ALUMIS INC.","ticker":"ALMS","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alumis reports 2025 net loss $243.3M; Phase 3 envudeucitinib meets endpoints; NDA plan 2H2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $243.3M vs. $294.2M in 2024; revenue $24.1M from Kaken license.","Cash, cash equivalents and marketable securities $308.5M at Dec 31, 2025.","Jan 2026 public offering raised $345.1M gross; net proceeds $324.4M extend runway into Q4 2027.","R&D expenses $386.0M, up 45% YoY, driven by Phase 3 ONWARD program and merger costs.","NDA for envudeucitinib in plaque psoriasis on track for 2H2026; SLE Phase 2b data expected 3Q2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2690080681.650258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109863,"accession_number":"0001104659-26-002265","cik":1847367,"company_name":"ALUMIS INC.","ticker":"ALMS","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Alumis prices public offering of 17.65M shares at $17/sh for ~$345M gross; prelim cash $308.6M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Public offering of 17,650,000 shares at $17.00 per share; gross proceeds ~$345.1 million.","Underwriters' option fully exercised on Jan 8, 2026 for additional 2,647,500 shares.","Preliminary unaudited cash, equivalents and marketable securities as of Dec 31, 2025: ~$308.6 million.","Closing expected Jan 9, 2026; led by Morgan Stanley, Leerink Partners and Cantor Fitzgerald."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2690080681.650258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109862,"accession_number":"0001104659-26-001073","cik":1847367,"company_name":"ALUMIS INC.","ticker":"ALMS","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Alumis Phase 3 oral psoriasis drug envudeucitinib meets all endpoints; NDA planned H2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Both ONWARD1 and ONWARD2 trials met co-primary endpoints PASI 75 and sPGA 0/1 at Week 16 (p<0.0001).","At Week 24, ~65% achieved PASI 90 and >40% PASI 100, on average across trials.","Safety profile consistent with Phase 2; most common TEAEs were headaches, nasopharyngitis, URIs, and acne.","Envudeucitinib also superior vs apremilast on PASI endpoints at Week 24 (p<0.0001).","Alumis to submit NDA to FDA in H2 2026; topline from SLE Phase 2b expected Q3 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":2690080681.650258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109861,"accession_number":"0001104659-26-000197","cik":1847367,"company_name":"ALUMIS INC.","ticker":"ALMS","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Alumis sends material breach notice to Climb Bio over $3M milestone; Climb Bio files declaratory judgment action","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Climb Bio failed to pay $3,000,000 Development Milestone due Jan 1, 2026 under the Asset Purchase Agreement.","Climb Bio filed a declaratory judgment action in Delaware Superior Court on Dec 31, 2025 claiming budoprutug is not a 'Product' under the APA.","Alumis intends to seek the $3M milestone payment, interest, indemnification for attorneys' fees and costs.","Total milestone payments under APA could reach $157.5M plus royalties and sublicense income per Climb Bio's SEC filings.","Alumis believes Climb Bio's position is contrary to the plain terms and intent of the APA and prior statements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2690080681.650258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126398,"accession_number":"0001847367-25-000048","cik":1847367,"company_name":"ALUMIS INC.","ticker":"ALMS","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alumis Q3 net loss $110.8M; cash $377.7M; Phase 3 psoriasis data expected Q1 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $110.8M for Q3 2025 vs. $93.1M in Q3 2024; R&D expenses rose to $97.8M from $87.8M.","Cash, cash equivalents and marketable securities totaled $377.7M as of September 30, 2025.","Topline Phase 3 ONWARD data for envudeucitinib in plaque psoriasis expected early Q1 2026; Phase 2b SLE data in Q3 2026.","Collaboration revenue of $2.1M from Kaken Pharmaceutical in Q3 2025.","Company expects existing cash to fund pipeline and operations into 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":22121000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2690080681.650258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143157,"accession_number":"0001104659-25-086612","cik":1847367,"company_name":"ALUMIS INC.","ticker":"ALMS","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Alumis releases updated September 2025 corporate presentation","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company filed updated corporate presentation dated September 2025 for use with investors.","Presentation covers corporate strategy and pipeline milestones; no financial data disclosed.","Full presentation content not available from filing excerpt; details limited."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2690080681.650258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143156,"accession_number":"0001847367-25-000039","cik":1847367,"company_name":"ALUMIS INC.","ticker":"ALMS","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alumis Q2 net income $59.3M (incl. $187.9M merger gain); Phase 3 psoriasis & Phase 2b SLE enrollment complete","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities of $486.3M as of June 30, 2025; expects to fund operations into 2027.","Phase 3 ONWARD trials (psoriasis) fully enrolled; topline data expected early Q1 2026.","Phase 2b LUMUS trial (SLE) fully enrolled with 408 patients; topline data expected Q3 2026.","Completed merger with ACELYRIN, adding $382.6M cash; total merger-related expenses of $26.8M in Q2.","R&D expenses $108.8M (up from $48.6M); G&A $34.5M (up from $7.6M) driven by merger costs and clinical acceleration."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":20055000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2690080681.650258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143155,"accession_number":"0001104659-25-073628","cik":1847367,"company_name":"ALUMIS INC.","ticker":"ALMS","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Alumis stockholders elect two Class I directors, ratify PwC as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Srinivas Akkaraju (55,095,965 for) and Sapna Srivastava (54,546,203 for) elected Class I directors.","Ratification of PricewaterhouseCoopers LLP as FY2025 auditor approved (78,973,998 for, 84,524 against).","Meeting held July 30, 2025; 96,004,357 shares entitled to vote; standard procedural agenda."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2690080681.650258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161278,"accession_number":"0001847367-25-000035","cik":1847367,"company_name":"ALUMIS INC.","ticker":"ALMS","form_type":"8-K/A","filed_at":"2025-06-30T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Alumis files ACELYRIN financials: 2024 net loss $248M, cash $448M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["ACELYRIN's FY2024 net loss $248.2M, down from $381.6M in 2023; no revenue.","Cash, cash equivalents and short-term marketable securities $448.4M at Dec 31, 2024.","Accumulated deficit $736.9M; R&D expenses $238.1M in 2024.","Merger closed May 21, 2025; Alumis files audited 2024/2023 and unaudited Q1 2025 financials.","Pro forma financial information in Exhibit 99.3 reflects combined entity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2690080681.650258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161282,"accession_number":"0001104659-25-051338","cik":1847367,"company_name":"ALUMIS INC.","ticker":"ALMS","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["2.01","5.02","8.01","9.01"],"status":"ready","headline":"Alumis completes merger with ACELYRIN; cash runway extended into 2027","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Each ACELYRIN share exchanged for 0.4814 shares of Alumis common stock; ACELYRIN stock ceased trading.","Lynn Tetrault appointed to Alumis board; Henry Gosebruch will not join due to new CEO role at Galapagos.","Combined company cash runway extends into 2027, supporting multiple planned data readouts.","Martin Babler remains President, CEO, and Chairman of Alumis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":2690080681.650258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161281,"accession_number":"0001104659-25-050436","cik":1847367,"company_name":"ALUMIS INC.","ticker":"ALMS","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Alumis shareholders approve ACELYRIN merger; expected to close May 21, 2025","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Stock issuance proposal approved: 41,861,422 For, 159,077 Against, 1,406 Abstain.","Adjournment proposal approved: 41,757,390 For, 261,875 Against, 2,640 Abstain.","Expected closing date May 21, 2025, subject to Nasdaq listing and SEC S-4 effectiveness.","Record date April 1, 2025; 42,021,905 shares voted (~89% of outstanding)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2690080681.650258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161280,"accession_number":"0001847367-25-000026","cik":1847367,"company_name":"ALUMIS INC.","ticker":"ALMS","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alumis Q1 net loss $99M, revenue $17.4M; merger with ACELYRIN on track for Q2 2025 close","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $99M in Q1 2025 vs $49.8M in Q1 2024; revenue of $17.4M from Kaken license fee.","Cash and marketable securities $208.7M as of March 31, 2025; combined pro forma cash $737M with ACELYRIN.","Merger with ACELYRIN approved by Alumis stockholders; exchange ratio 0.4814; expected close in Q2 2025.","ESK-001 Phase 3 psoriasis topline data expected early Q1 2026; SLE Phase 2b data in 2026.","R&D expenses $96.6M (up 130% YoY) driven by Phase 3 ONWARD program acceleration."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":17389000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":2690080681.650258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161279,"accession_number":"0001104659-25-036483","cik":1847367,"company_name":"ALUMIS INC.","ticker":"ALMS","form_type":"8-K","filed_at":"2025-04-21T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Alumis and ACELYRIN amend merger terms; ACELYRIN stockholders get 48% ownership of combined company","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Exchange ratio revised to 0.4814 Alumis shares per ACELYRIN share, up from original terms; Alumis stockholders own ~52%, ACELYRIN ~48% fully diluted.","Special Meeting of Stockholders for both companies scheduled for May 13, 2025; record date April 1, 2025.","Pro forma cash position of combined company ~$737M as of Dec 31, 2024; runway expected into 2027 for key data readouts.","Stockholders representing ~62% of Alumis and ~24% of ACELYRIN have entered into voting agreements supporting the transaction.","Merger expected to close in Q2 2025, subject to stockholder approvals and customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2690080681.650258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179437,"accession_number":"0001104659-25-027444","cik":1847367,"company_name":"ALUMIS INC.","ticker":"ALMS","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Alumis licenses ESK-001 to Kaken for Japan; $40M upfront/near-term plus $140M milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Alumis receives $20M upfront and $20M co-development payments from Kaken in 2025-2026.","Kaken gets exclusive rights to develop/commercialize ESK-001 for dermatology in Japan, with options for rheumatology and GI.","Alumis retains rights outside Japan; Kaken contributes to global development costs.","Cash runway extended through Phase 3 ONWARD psoriasis topline data readout.","Tiered royalties on Japan net sales: low double-digits to twenties percent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2690080681.650258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179436,"accession_number":"0001847367-25-000010","cik":1847367,"company_name":"ALUMIS INC.","ticker":"ALMS","form_type":"8-K","filed_at":"2025-03-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alumis 2024 net loss $294.2M, cash $288.3M; ACELYRIN merger expected Q2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $294.2M in 2024 vs $155.0M in 2023; R&D expenses rose to $265.6M from $137.7M.","Cash, cash equivalents and marketable securities of $288.3M as of Dec 31, 2024.","All-stock merger with ACELYRIN; pro forma cash ~$737M; Alumis stockholders to own ~55% on diluted basis.","Phase 3 ESK-001 psoriasis topline data expected Q1 2026; Phase 2 MS trial for A-005 to start 2H 2025.","Appointed Jack Danilkowicz as CCO and Sara Klein as CLO to bolster late-stage capabilities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2690080681.650258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179435,"accession_number":"0001104659-25-024616","cik":1847367,"company_name":"ALUMIS INC.","ticker":"ALMS","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Alumis and ACELYRIN release merger presentation update (limited details)","summary_kind":"llm","event_type":"m_and_a","confidence":"low","bullets":["Alumis and ACELYRIN released an updated merger presentation on March 18, 2025 (original announcement Feb 6, 2025).","No specific financial terms or changes disclosed in the 8-K filing; presentation content not fully available in this extract.","The presentation is intended to provide supplemental materials for shareholders evaluating the merger."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2690080681.650258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179434,"accession_number":"0001104659-25-021990","cik":1847367,"company_name":"ALUMIS INC.","ticker":"ALMS","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Alumis reports positive 52-week Phase 2 OLE data for ESK-001 in plaque psoriasis at AAD 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ESK-001 40 mg BID achieved PASI 90 61.3%, PASI 100 38.8%, sPGA 0 38.8% at Week 52 (mNRI, n=80).","Responses sustained or improved vs Week 12; 80% of ≥PASI-75 responders at Week 12 maintained or improved at Week 52.","No new safety findings; most TEAEs mild-to-moderate and self-limited.","Phase 3 ONWARD program ongoing; topline data expected Q1 2026.","Patient-reported outcomes: DLQI 0/1 61.3% and itch NRS≤4 81.3% at Week 52."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2690080681.650258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179433,"accession_number":"0001104659-25-020039","cik":1847367,"company_name":"ALUMIS INC.","ticker":"ALMS","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Alumis and ACELYRIN reaffirm all-stock merger; pro forma cash ~$737M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Alumis and ACELYRIN reaffirm commitment to merge in an all-stock transaction expected to close Q2 2025.","Pro forma cash of ~$737M as of Dec 31, 2024 provides runway into 2027.","Alumis had ~$289M cash, ACELYRIN ~$448M (preliminary, each as of Dec 31, 2024).","Combined portfolio includes ESK-001 (psoriasis, lupus), lonigutamab (thyroid eye disease), A-005 (multiple sclerosis).","Transaction subject to stockholder approvals and customary closing conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2690080681.650258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179432,"accession_number":"0001104659-25-016134","cik":1847367,"company_name":"ALUMIS INC.","ticker":"ALMS","form_type":"8-K","filed_at":"2025-02-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Alumis adopts severance plan providing up to 18 months salary, full equity acceleration on change of control","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Plan provides cash severance of 6-18 months base salary (plus 1-1.5x target bonus) for qualifying terminations within 12 months of a change of control.","Outside change of control, benefits range from 3-12 months base salary plus pro-rata bonus and COBRA; executive officers also get equity acceleration.","Eligibility requires signed participation agreement and execution of a release; equity acceleration applies to outstanding awards held by participants.","Plan effective February 18, 2025; supersedes prior severance arrangements for eligible employees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2690080681.650258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179431,"accession_number":"0001104659-25-010169","cik":1847367,"company_name":"ALUMIS INC.","ticker":"ALMS","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["1.01","2.02","7.01","8.01","9.01"],"status":"ready","headline":"Alumis to acquire ACELYRIN in all-stock merger; exchange ratio 0.4274","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Alumis to acquire ACELYRIN via merger; each ACELYRIN share converted into 0.4274 Alumis shares.","Stock options with exercise price ≤$18.00 converted to Alumis options at adjusted strike; options >$18.00 cancelled for no consideration.","Termination fees of $10M each; close targeted by July 7, 2025, subject to stockholder approvals and regulatory conditions.","Alumis reports preliminary cash, equivalents and marketable securities of ~$289M as of Dec 31, 2024.","Voting agreements cover ~24% of ACELYRIN shares and ~62% of Alumis shares; stockholders commit to vote for merger."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":2690080681.650258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196136,"accession_number":"0001104659-24-122282","cik":1847367,"company_name":"ALUMIS INC.","ticker":"ALMS","form_type":"8-K","filed_at":"2024-11-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Alumis updates LUMUS Phase 2 trial timeline on ClinicalTrials.gov","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Revised primary completion and study completion dates for LUMUS trial (ESK-001 in SLE) posted November 22, 2024.","LUMUS is a global, randomized, double-blind, placebo-controlled Phase 2 trial.","Company states the revisions conform with prior SEC filings and public guidance.","No specific new dates or financial impact disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2690080681.650258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196135,"accession_number":"0001104659-24-117704","cik":1847367,"company_name":"ALUMIS INC.","ticker":"ALMS","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alumis reports Q3 net loss of $93.1M; cash of $361.9M funds operations into 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $93.1M in Q3 2024 vs $43.4M in Q3 2023; R&D expenses rose to $87.8M from $37.8M, including $23M milestone payment for FronThera acquisition.","Cash and marketable securities of $361.9M as of Sept 30, 2024, expected to fund operations into 2026.","ESK-001 Phase 3 ONWARD psoriasis trials on track; topline results expected H1 2026. Phase 2b SLE data expected 2026.","A-005 Phase 1 data expected by year-end 2024; Phase 2 MS trial initiation planned 2025.","Presented EADV data: ESK-001 40mg BID achieved 93% PASI 75 at 28 weeks (observed); supports ongoing Phase 3 dose."],"consensus_eps_estimate":null,"consensus_eps_actual":-10.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2690080681.650258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212419,"accession_number":"0001104659-24-088956","cik":1847367,"company_name":"ALUMIS INC.","ticker":"ALMS","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alumis Q2 net loss $56.5M, cash $209.5M; Phase 3 psoriasis trial initiated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $56.5M for Q2 2024 vs $36.3M in Q2 2023; R&D expense $48.6M (up from $32.8M).","Cash and marketable securities $209.5M at June 30; IPO net proceeds $233.2M extend runway into 2026.","Initiated ESK-001 Phase 3 ONWARD program in moderate-to-severe plaque psoriasis; topline expected 2026.","Completed IPO and concurrent private placement raising $250M gross proceeds (15.625M shares at $16.00).","Phase 1 trial for A-005 (CNS-penetrant TYK2 inhibitor) dosed first healthy volunteer in April 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-44.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2690080681.650258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212418,"accession_number":"0001104659-24-080852","cik":1847367,"company_name":"ALUMIS INC.","ticker":"ALMS","form_type":"8-K","filed_at":"2024-07-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Alumis closes $40M private placement of 2.5M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed sale of 2,500,000 shares of common stock for gross proceeds of $40M.","Implied price of $16.00 per share based on $40M total and 2.5M shares.","Placement closed on July 17, 2024, fulfilling June 27 purchase agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2690080681.650258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212417,"accession_number":"0001104659-24-077762","cik":1847367,"company_name":"ALUMIS INC.","ticker":"ALMS","form_type":"8-K","filed_at":"2024-07-03T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Alumis raises $40M in PIPE at $16/share from AyurMaya, tied to IPO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreed to sell 2.5M shares of common stock to AyurMaya at $16.00/share for $40M total.","Private placement closes on or before July 22, 2024, concurrent with IPO closing.","Shares are unregistered, sold under Rule 506(b) of Regulation D.","Proceeds provide IPO-related capital; Investor gets registration rights from existing investors’ rights agreement.","Transaction entered June 27, 2024; stock trades on Nasdaq under ALMS."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2690080681.650258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212416,"accession_number":"0001104659-24-076815","cik":1847367,"company_name":"ALUMIS INC.","ticker":"ALMS","form_type":"8-K","filed_at":"2024-07-01T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Alumis files amended charter and bylaws upon IPO close on July 1, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed amended and restated certificate of incorporation with Delaware Secretary of State.","Adopted amended and restated bylaws effective immediately before IPO closing.","Both documents previously approved by board and stockholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":2690080681.650258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}